VistaGen Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.514; its P/E ratio is -1.35; VistaGen Therapeutics is scheduled to report earnings on June 25, 2024, and the estimated EPS forecast is $-0.36. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22
Income Statement	-
Total Revenue	$ 411.40K	$ 277.70K	-	-	-
Gross Profit	$ 411.40K	$ 277.70K	-	-	$ 179.60K
EBIT	$ -7.88M	$ -6.78M	$ -7.00M	-	$ -9.77M
EBITDA	$ -7.74M	-	$ -6.86M	-	$ -9.63M
Net Income Common Stockholders	$ -6.35M	$ -6.59M	$ -6.90M	-	$ -9.76M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 126.56M	$ 37.61M	$ 9.62M	$ 16.64M	$ 25.04M
Total Assets	$ 131.07M	$ 42.20M	$ 15.03M	$ 21.09M	$ 29.71M
Total Debt	$ 2.25M	$ 2.38M	$ 2.50M	$ 2.61M	$ 2.73M
Net Debt	$ -124.30M	$ -35.23M	$ -7.12M	$ -14.02M	$ -22.31M
Total Liabilities	$ 7.78M	$ 6.55M	$ 8.18M	$ 8.90M	$ 9.03M
Stockholders Equity	$ 123.28M	$ 35.65M	$ 6.85M	$ 12.08M	$ 20.67M
Cash Flow	-
Free Cash Flow	$ -4.54M	-	$ -7.89M	-	$ -9.95M
Operating Cash Flow	$ -4.54M	$ -6.19M	$ -7.89M	-	$ -9.93M
Investing Cash Flow	$ -32.30K	-	-	-	$ -12.50K
Financing Cash Flow	$ 93.52M	$ 34.18M	$ 875.60K	-	$ -304.10K

Currency in USD

VistaGen Therapeutics Earnings and Revenue History

Income Statement >

VistaGen Therapeutics Debt to Assets

Balance Sheet >

VistaGen Therapeutics Cash Flow

Cash Flow >

VistaGen Therapeutics Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing